<DOC>
	<DOCNO>NCT01310205</DOCNO>
	<brief_summary>This extension ongoing study SCI-SCV-HCV-P2-001 subject invite participate extension study complete treatment study SCI-SCV-HCV-P2-001 eligible retreatment peg-IFN RBV .</brief_summary>
	<brief_title>Extension Study SCI-SCV-HCV-P2-001 : Long-Term FU Subj Who Opt Retreatment With Peg-INF RBV After Completing Treatment HCV</brief_title>
	<detailed_description>In extension study , subject ask give permission share HCV RNA viral load test result , obtain local laboratory , different time point also ask give permission share SOC dose information ( peg-IFN RBV ) . As SCV-07 treatment , procedure , assessment require extension study , relate safety information collect . The study last 72 week subject complete treatment study SCI-SCV-HCV-P2-001 begin retreatment peg-IFN RBV .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<criteria>Subjects satisfy follow criterion may enrol study : Subjects must able understand sign ICF approve investigator 's institutional review board ( IRB ) study ; must complete treatment study SCISCVHCVP2001 ; must , judgment investigator , able benefit retreatment per current SOC ( pegIFN RBV ) . Subjects satisfy follow criterion enrol study : Subjects , opinion investigator , unable tolerate retreatment pegIFN RBV least 48 week high risk early treatment discontinuation plan participate another investigational trial prior provide final sample trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2011</verification_date>
	<keyword>HCV</keyword>
	<keyword>Genotype 1</keyword>
	<keyword>relapsers</keyword>
	<keyword>non cirrhotic</keyword>
	<keyword>Chronic Hepatitis C</keyword>
</DOC>